Media.Player

Novel Agents to Enhance Tolerance to an Immunogen

技術應用

Biotech & Biological Sciences

詳細技術說明

Acquired immunologic protection against foreign antigens often requires the administration of varying, and often unknown, amounts of the antigen to create the desired protective mechanisms. Successful achievement of immunologic protection also depends upon systemic unresponsiveness to the foreign antigen as it is being administered during the adaptation phase. Though the precise mechanisms by which delivery of antigen elicits a state of systemic unresponsiveness are not fully understood, the dosage of antigen has been shown to be an important factor. The IP discussed herein is a ligand protein which can be fused to a broad range of antigens enabling tolerance to a number of autoimmune diseases, inflammatory diseases, other allergens and biologic therapeutic molecules (e.g., botulinum toxin). Furthermore, the addition of a tolerizing agent mediates tolerance after a single oral dose or with minimal dosing; eliminating the problem of conventional tolerization regimens that require high doses or repeated dosing of antigen. In addition, studies have shown that the fusion protein is capable of regulating peripheral tolerance to either nasal or oral delivery providing convenience for the patient and increased patient compliance. This IP cures MS in a mouse model in 24 hours.

*Abstract

A new approach to developing highly virulent, antigen-specific agents, called ΓÇ£tolerizing agentsΓÇØ, uses a mucosal targeting ligand fused to a specific antigen to induce host unresponsiveness solely to that antigen while avoiding global immune suppression.

*Principal Investigation

Name: David W. Pascual , Professor

Department: Immunology & Infectious Diseases

Name: Kohtaro Fujihashi , Professor Dentistry DMD

Department: Pediatric Dentistry

Name: Massimo Maddaloni , Research Assistant Professor

Department: Immunology & Infectious Diseases

附加資料

Patent Number: US7910113B2
Application Number: US2008294380A
Inventor: Pascual, David W. | Fujihashi, Kohtaro | Maddaloni, Massimo
Priority Date: 27 Mar 2006
Priority Number: US7910113B2
Application Date: 24 Sep 2008
Publication Date: 22 Mar 2011
IPC Current: A61K003915 | A61K003900 | C07K001400 | C07K001414
US Class: 4242151 | 4241841 | 4241921 | 530350
Assignee Applicant: Montana State University,Bozeman,MT | UAB Research Foundation,Birmingham
Title: Tolerizing agents
Usefulness: Tolerizing agents
Summary: The fusion protein is useful in inducing in a subject tolerance to the antigen or allergen.
Novelty: New tolerizing fusion protein comprising a targeting portion and an antigen or allergen to which tolerance is desired, useful in inducing in a subject tolerance to the antigen or allergen

主要類別

生物醫學

細分類別

醫藥成分

國家/地區

美國